COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,026 Articles (22,627 medRxiv, 8,399 bioRxiv)

Most recent first Previous |  Page 149: Articles 1481-1490  | Next

Development of ketobenzothiazole-based peptidomimetic TMPRSS13 inhibitors with low nanomolar potency
Joushomme, A., Desilets, A., Champagne, W., Hassanzadeh, M., Lemieux, G., Gravel-Trudeau, A., Lepage, M., Lafreniere, S., Froehlich, U., List, K., Boudreault, P.-L., Leduc, R.
10.1101/2024.08.28.609965 — Posted: 2024-08-29
FAIR assessment of MINERVA as an opportunity to foster open science and scientific crowdsourcing in systems biomedicine
Balaur, I., Welter, D., Rougny, A., Inau, E. T., Mazein, A., Ghosh, S., Schneider, R., Waltemath, D., Ostaszewski, M., Satagopam, V.
10.1101/2024.08.28.610042 — Posted: 2024-08-29
The post-viral GPNMB+ immune niche persists in long-term Covid, asthma, and COPD
Wu, K., Zhang, Y., Yin-DeClue, H., Sun, K., Mao, D., Crouch, E. C., Byers, D. E., Holtzman, M. J.
10.1101/2024.08.27.24312640 — Posted: 2024-08-28
Unsupervised detection of SARS-CoV-2 mutations and lineages in Norwegian wastewater samples using long-read sequencing
Garcia, I., Riis, R. K., Moen, L. V., Rohringer, A., Madslien, E. H., Bragstad, K.
10.1101/2024.08.27.24312690 — Posted: 2024-08-28
Short- and Long-term Outcomes of children hospitalized with COVID-19 or Influenza: results of the AUTCOV study
Wagenlechner, C., Wendt, R., Reichardt, B., Mildner, M., Mascherbauer, J., Aigner, C., Auer, J., Ankersmit, H. J., Graf, A.
10.1101/2024.08.28.24312702 — Posted: 2024-08-28
Loss to follow-up of ambulatory patients in the transition to telemedicine in the COVID-19 pandemic at a reference center for mental health in Lima, Peru.
Ruiz-Grosso, P., Zevallos-Bustamante, S., Sagastegui, A.
10.1101/2024.08.27.24312689 — Posted: 2024-08-28
SARS-CoV-2 Surveillance in US Wastewater: Leading Indicators and Data Variability Analysis in the 2023-2024 Season
Schenk, H., Rauch, W., Zulli, A., Boehm, A.
10.1101/2024.08.28.24312739 — Posted: 2024-08-28
An Equity-Focused Comprehensive Analysis of COVID-19 Vaccine Rollout and Prioritization Strategies Across Six Canadian Provinces: Addressing the Needs of Vulnerable and High-Risk Populations
Sobers, M., Atukorale, V., Mauer-Vakil, D., Bashir, K., Ouedraogo, M. O., Dharma, C., Ataullahjan, A., Fadel, S. A., Allin, S.
10.1101/2024.08.28.24312721 — Posted: 2024-08-28
Identification of a new ORF3a-E fusion subgenomic RNA of SARS-CoV-2 and its biological features in the infection process
Zhang, Y., Zheng, H., Li, J., Zhang, X., Zhang, X., Li, J., Li, H., Zhao, X., Zhang, Z., Li, Y., Chen, k., Peng, S., Zhang, Y., Shi, H., Liu, L.
10.1101/2024.08.28.610093 — Posted: 2024-08-28
Molecular basis of convergent evolution of ACE2 receptor utilization among HKU5 coronaviruses
Park, Y.-J., Liu, C., Lee, J., Brown, J. T., Ma, C.-B., Liu, P., Xiong, Q., Stewart, C., Addetia, A., Craig, C. J., Tortorici, M. A., Alshukari, A., Starr, T., Yan, H., Veesler, D.
10.1101/2024.08.28.608351 — Posted: 2024-08-28

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).